Hemiasterlin
- Generic Name
- Hemiasterlin
A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00165802
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center - University of Miami, Miami, Florida, United States
🇺🇸Cancer Institute Of New Jersey, New Brunswick, New Jersey, United States
A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00130169
- Locations
- 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States
🇺🇸University Hospital Medical Center - SUNY at Stony Brook, Stony Brook, New York, United States
An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT00121732
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸CTRC, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath